Advanced Search

Journal of Traditional Chinese Medicine >

2024 , Vol. 44 >Issue 1: 122 - 130

DOI: https://doi.org/10.19852/j.cnki.jtcm.20231215.001

Original articles

Efficacy of Ganshuang granules (肝爽颗粒) on non-alcoholic fatty liver and underlying mechanism: a network pharmacology and experimental verification

  • Guoguo ZHI ,
  • Bingjie SHAO ,
  • Tianyan ZHENG ,
  • Shaoxiu JI ,
  • Jingwei LI ,
  • Yanni DANG ,
  • Feng LIU ,
  • Dong WANG
Expand
  • 1 School of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China
    2 Shanxi Buchang Pharmaceutical Company, Limited, Xi’an 712000, China

Received date: 2022-12-22

  Accepted date: 2023-04-04

  Online published: 2023-12-15

Supported by

Chengdu University of Traditional Chinese Medicine: Application of A Mouse Model to Explore the Mechanism of Therapeutic Action of Safranin in Type 2 Diabetes Mellitus(YXRC2018003)

Fold

Abstract

OBJECTIVE: To investigate the potential pharmacological mechanisms of Ganshuang granules (肝爽颗粒, GSG) in treating non-alcoholic fatty liver (NAFLD).

METHODS: All the active components and targets of GSG were retrieved from the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform. Protein-Protein interaction network, Kyoto Encyclopedia of Genes and Genomes and Gene Ontology function annotation of common targets were analyzed to predict the mechanisms of action of GSG in the treatment of NAFLD. Then, the mouse models of NAFLD were constructed in a diet-induced manner and treated with GSG. The levels of interleukin 6 (IL-6), tumor necrosis factor-alpha (TNF-α) and phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT) pathway-related proteins in the liver of mice in each group were measured by enzyme linked immunosorbent assay and Western blot, respectively.

RESULTS: Network pharmacology revealed a total of 159 potential targets of GSG for the treatment of NAFLD. Functional enrichment analysis indicated that the PI3K/AKT signaling pathway may be involved during GSG treatment of NAFLD. Further experiments showed that the significantly decreased alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, total cholesterol, triglyceride and low-density lipoprotein cholesterol levels in NAFLD model mice serum after GSG treatment, as well as the expression levels of IL-6 and TNF-α in the liver. Furthermore, drug intervention increased the protein expression levels of phosphorylated-PI3K (P-PI3K) and P-AKT in the liver of the model group mice, and decreased the protein expression level of sterol regulatory element-binding protein 1.

CONCLUSION: We found that GSG is effective in treating NAFLD and the potential therapeutic targets may be involved in PI3K/AKT signaling pathway.

Key words： fatty liver, alcoholic; network pharmacology; models, animal; phosphatidylinositol 3-kinase; proto-oncogene proteins c-akt; signal transduction; Ganshuang granules

Cite this article

Guoguo ZHI , Bingjie SHAO , Tianyan ZHENG , Shaoxiu JI , Jingwei LI , Yanni DANG , Feng LIU , Dong WANG . Efficacy of Ganshuang granules (肝爽颗粒) on non-alcoholic fatty liver and underlying mechanism: a network pharmacology and experimental verification[J]. Journal of Traditional Chinese Medicine, 2024 , 44(1) : 122 -130 . DOI: 10.19852/j.cnki.jtcm.20231215.001

References

1. Eslam M, Valenti L, Romeo S. Genetics and epigenetics of NAFLD and NASH: clinical impact. J Hepatol 2018; 68: 268-79.
2. Sodum N, Kumar G, Bojja SL, Kumar N, Rao CM. Epigenetics in NAFLD/NASH: targets and therapy. Pharmacol Res 2021; 167: 105484.
3. Chen G, Ni Y, Nagata N, Xu L, Ota T. Micronutrient antioxidants and nonalcoholic fatty liver disease. Int J Mol Sci 2016; 17: 1379.
4. Zeigerer A. NAFLD-a rising metabolic disease. Mol Metab 2021; 50: 101274.
5. Li J, Zou B, Yeo YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2019; 4: 389.
6. Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 2016; 65: 1038-48.
7. Cobbina E, Akhlaghi F. Non-alcoholic fatty liver disease (NAFLD)- pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug Metab Rev 2017; 49: 197-211.
8. Safari Z, Gérard P. The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD). Cell Mol Life Sci 2019; 76: 1541-58.
9. Lau LHS, Wong SH. Microbiota, obesity and NAFLD. Adv Exp Med Biol 2018; 1061: 111-25.
10. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998; 114: 842-5.
11. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018; 67: 328-57.
12. Chen M, Xie Y, Gong S, et al. Traditional Chinese Medicine in the treatment of nonalcoholic steatohepatitis. Pharmacol Res 2021; 172: 105849.
13. Yang JY, Tao DQ, Ma W, et al. Protective effects and mechanisms of Lizhong decoction against non-alcoholic fatty liver disease in a rat model. J Tradit Chin Med 2022; 42: 773-80.
14. Li XL, Sun FX, Shang ZM, Zhang YX, Li J, Zhang QX. Effect of Dangfei Liganning capsule on liver X receptor α/steroid regulatory element binding protein-1/fatty acid synthase signal pathway in rats with metabolic- associated fatty liver disease. J Tradit Chin Med 2022; 42: 940-7.
15. Pang XC, Kang D, Fang JS, et al. Network pharmacology-based analysis of Chinese herbal Naodesheng formula for application to Alzheimer's disease. Chin J Nat Med 2018; 16: 53-62.
16. Gou X, Gao Z, Yang Y, et al. State-target strategy: a bridge for the integration of Chinese and Western Medicine. J Tradit Chin Med 2021; 41: 1-5.
17. Sun HQ, Wang XQ, Shi HB, Lou JL, Chen Y, Duan ZP. Ganshuang granules protect mouse liver from chronic injury induced by CCl4 via autophagy. Lin Chuang Gan Dan Bing Za Zhi 2015; 31: 1114-9.
18. Liu L LJ, Liu CY, et al. Effect of tenofovir combined with Ganshuang granule on hemodynamics of portal vein system in hepatitis B liver cirrhosis. Lin Chuang Gan Dan Bing Za Zhi 2021; 42: 134-9.
19. Lu F, Geng JB, Zhang JW, Dong Y. Effect of entecavir plus Ganshuang granule on fibrosis and cirrhosis in patients with chronic hepatitis B. J Tradit Chin Med 2021; 41: 624-9.
20. Li S, Zhang B. Traditional Chinese Medicine network pharmacology: theory, methodology and application. Chin J Nat Med 2013; 11: 110-20.
21. Kaixuan Z, Dong Z, Huiwei B, Lijing LI. Network pharmacology and molecular docking study on the effect of Kaempferol in treatment of metabolic associated fatty liver disease. J Tradit Chin Med 2022; 42: 788-94.
22. Ru J, Li P, Wang J, et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. J Cheminform 2014; 6: 13.
23. Huang J, Cheung F, Tan HY, et al. Identification of the active compounds and significant pathways of Yinchenhao decoction based on network pharmacology. Mol Med Rep 2017; 16: 4583-92.
24. Soudy M, Anwar AM, Ahmed EA, et al. UniprotR: retrieving and visualizing protein sequence and functional information from Universal Protein Resource (UniProt knowledgebase). J Proteomics 2020; 213: 103613.
25. Li WH, Han JR, Ren PP, Xie Y, Jiang DY. Exploration of the mechanism of Zisheng Shenqi decoction against gout arthritis using network pharmacology. Comput Biol Chem 2021; 90: 107358.
26. Stelzer G, Rosen N, Plaschkes I, et al. The GeneCards Suite: from gene data mining to disease genome sequence analyses. Curr Protoc Bioinformatics 2016; 54: 1.30. 1-33.
27. Davis AP, Grondin CJ, Johnson RJ, et al. Comparative toxicogenomics database (CTD): update 2021. Nucleic Acids Res 2021; 49: D1138-43.
28. Amberger JS, Hamosh A. Searching online mendelian inheritance in man (OMIM): a knowledgebase of human genes and genetic phenotypes. Curr Protoc Bioinformatics 2017; 58: 1.2. 1-12.
29. He D, Li Q, Du G, Meng G, Sun J, Chen S. An integration of network pharmacology and experimental verification to investigate the mechanism of Guizhi to treat nephrotic syndrome. Front Pharmacol 2021; 12: 755421.
30. Zhang W, Zhang L, Wang WJ, et al. Network pharmacology and in vitro experimental verification to explore the mechanism of Sanhua decoction in the treatment of ischaemic stroke. Pharm Biol 2022; 60: 119-30.
31. Wahab Khattak F, Salamah Alhwaiti Y, Ali A, Faisal M, Siddiqi MH. Protein-protein interaction analysis through network topology (Oral Cancer). J Healthc Eng 2021; 2021: 6623904.
32. Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003; 13: 2498-504.
33. Tang Y, Li M, Wang J, Pan Y, Wu FX. CytoNCA: a cytoscape plugin for centrality analysis and evaluation of protein interaction networks. Biosystems 2015; 127: 67-72.
34. Wan Y, Xu L, Liu Z, et al. Utilising network pharmacology to explore the underlying mechanism of Wumei pill in treating pancreatic neoplasms. BMC Complement Altern Med 2019; 19: 158.
35. Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics 2012; 16: 284-7.
36. Liu B, Deng X, Jiang Q, et al. Scoparone improves hepatic inflammation and autophagy in mice with nonalcoholic steatohepatitis by regulating the ROS/P38/Nrf 2 axis and PI3K/AKT/mTOR pathway in macrophages. Biomed Pharmacother 2020; 125: 109895.
37. Zhao Q, Lin X, Wang G. Targeting SREBP-1-mediated lipogenesis as potential strategies for cancer. Front Oncol 2022; 12: 952371.
38. Zeng S, Liu Y, Jiang C, Li B, Wen L, Feng Q. Clinical efficacy and safety of Ganshuang granules as an adjuvant treatment for chronic hepatitis B liver fibrosis: a protocol for systematic review and meta analysis. Medicine (Baltimore) 2020; 99: e22692.
39. Zhang R, Zhu X, Bai H, Ning K. Network pharmacology databases for Traditional Chinese Medicine: review and assessment. Front Pharmacol 2019; 10: 123.
40. Van De Wier B, Koek GH, Bast A, Haenen GR. The potential of flavonoids in the treatment of non-alcoholic fatty liver disease. Crit Rev Food Sci Nutr 2017; 57: 834-55.
41. Zhu Y, Liu R, Shen Z, Cai G. Combination of luteolin and lycopene effectively protect against the "two-hit" in NAFLD through Sirt1/AMPK signal pathway. Life Sci 2020; 256: 117990.
42. Abu-Elsaad N, El-Karef A. Protection against nonalcoholic steatohepatitis through targeting IL-18 and IL-1 alpha by luteolin. Pharmacol Rep 2019; 71: 688-94.
43. Yin Y, Gao L, Lin H, et al. Luteolin improves non-alcoholic fatty liver disease in db/db mice by inhibition of liver X receptor activation to down-regulate expression of sterol regulatory element binding protein 1c. Biochem Biophys Res Commun 2017; 482: 720-6.
44. Shanware NP, Bray K, Abraham RT. The PI3K, metabolic, and autophagy networks: interactive partners in cellular health and disease. Annu Rev Pharmacol Toxicol 2013; 53: 89-106.
45. Shaywitz AJ, Courtney KD, Patnaik A, Cantley LC. PI3K enters beta-testing. Cell Metab 2008; 8: 179-81.
46. Matsuda S, Kobayashi M, Kitagishi Y. Roles for PI3K/AKT/PTEN pathway in cell signaling of nonalcoholic fatty liver disease. ISRN Endocrinol 2013; 2013: 472432.
47. Huang X, Liu G, Guo J, Su Z. The PI3K/AKT pathway in obesity and type 2 diabetes. Int J Biol Sci 2018; 14: 1483-96.
48. Fan Y, He Z, Wang W, et al. Tangganjian decoction ameliorates type 2 diabetes mellitus and nonalcoholic fatty liver disease in rats by activating the IRS/PI3K/AKT signaling pathway. Biomed Pharmacother 2018; 106: 733-7.
49. Wang H, Tan H, Zhan W, et al. Molecular mechanism of Fufang Zhenzhu Tiaozhi capsule in the treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease based on network pharmacology and validation in minipigs. J Ethnopharmacol 2021; 274: 114056.
50. Gu H, Jiang W, You N, et al. Soluble Klotho improves hepatic glucose and lipid homeostasis in type 2 diabetes. Mol Ther Methods Clin Dev 2020; 18: 811-23.
51. Zeng L, Tang WJ, Yin JJ, Zhou BJ. Signal transductions and nonalcoholic fatty liver: a mini-review. Int J Clin Exp Med 2014; 7: 1624-31.
52. Zhang J, Feng Q. Pharmacological effects and molecular protective mechanisms of astragalus polysaccharides on nonalcoholic fatty liver disease. Front Pharmacol 2022; 13: 854674.
53. Chen Z, Yu R, Xiong Y, Du F, Zhu S. A vicious circle between insulin resistance and inflammation in nonalcoholic fatty liver disease. Lipids Health Dis 2017; 16: 203.
54. Risso G, Blaustein M, Pozzi B, Mammi P, Srebrow A. Akt/PKB: one kinase, many modifications. Biochem J 2015; 468: 203-14.
55. Jalali A, Zarshenas MM. AKT/GSK-3 pathway targeting; botanicals and bioactive compounds with anticancer activities. Curr Pharm Des 2021; 27: 3091-104.
56. Revathidevi S, Munirajan AK. Akt in cancer: mediator and more. Semin Cancer Biol 2019; 59: 80-91.
57. Porta C, Paglino C, Mosca A. Targeting PI3K/Akt/mTOR signaling in cancer. Front Oncol 2014; 4: 64.
58. Hinz N, Jücker M. Distinct functions of AKT isoforms in breast cancer: a comprehensive review. Cell Commun Signal 2019; 17: 154.
59. Jump DB. Fatty acid regulation of hepatic lipid metabolism. Curr Opin Clin Nutr Metab Care 2011; 14: 115-20.
60. Xiao X, Song BL. SREBP: a novel therapeutic target. Acta Biochim Biophys Sin (Shanghai) 2013; 45: 2-10.
61. Li L, Yang J, Li F, Gao F, Zhu L, Hao J. FBXW7 mediates high glucose-induced SREBP-1 expression in renal tubular cells of diabetic nephropathy under PI3K/Akt pathway regulation. Mol Med Rep 2021; 23: 233.
62. Hao J, Liu S, Zhao S, et al. PI3K/Akt pathway mediates high glucose-induced lipogenesis and extracellular matrix accumulation in HKC cells through regulation of SREBP-1 and TGF-β1. Histochem Cell Biol 2011; 135: 173-81.
Options
Outlines

/

〈 〉